Evidence map›Paper›PMID 22848740›Full record

ArticlePloS one2012

FOXO3 is a glucocorticoid receptor target and regulates LKB1 and its own expression based on cellular AMP levels via a positive autoregulatory loop.

Nicolas Lützner, Hubert Kalbacher, Anja Krones-Herzig, Frank Rösl

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 100 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Long-Term Epigenetic Regulation ofInternational journal of molecular sciences · 2024
    Article
  10. FOXO family isoforms.Cell death & disease · 2023
    Review
  11. FoxO3 Modulates Circadian Rhythms in Neural Stem Cells.International journal of molecular sciences · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. miRNAs in Lymphocytic Leukaemias-The miRror of Drug Resistance.International journal of molecular sciences · 2022
    Review
  16. Evaluation of the Effect ofMolecular syndromology · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Nicolas LütznerResearch Program Infections and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. nicolas.luetzner@web.de
Hubert Kalbacher
Anja Krones-Herzig
Frank Rösl
German Cancer Research Center · DEHeidelberg University · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FOXO3 is a transcription factor involved in the regulation of multiple physiological processes including cell cycle arrest, apoptosis, oxidative stress-response and energy metabolism. Although much is known about its post-translational modification, the transcriptional regulation of FOXO3, as well as the cross-talk between transcription and post-translational events, is still poorly understood. In the present study, we show that FOXO3 is an immediate early glucocorticoid receptor (GR) target, whose transcription is even further enhanced by conditions that mimic metabolic stress. Induction of FOXO3 transcription by GR-binding steroids was reversed by concomitant treatment with the GR antagonist RU-486, but further enhanced by stimuli that activate the AMP-activated protein kinase (AMPK). Analysis of genomic DNA and chromatin immunoprecipitation, as well as luciferase reporter assays, revealed two functional glucocorticoid responsive elements within the FOXO3 promoter. Furthermore, we provide functional evidence for a phosphorylation switch that explains how glucocorticoids induce transcriptional activation of the gene but subsequently inactivate the corresponding protein by site-specific phosphorylation. Only when AMPK is stimulated, pre-existing FOXO3 becomes reverted toward an active form. Energy deprived conditions thus activate FOXO3 on two different levels, namely transcriptional and post-translational. In that way, FOXO3 acts as a metabolic stress sensor that coordinates expression of LKB1, the master upstream kinase involved in metabolic sensing, depending on the energy status of the cell. Additionally, we show that FOXO3 binds and activates its own promoter via a positive autoregulatory feedback loop. In conclusion, our data explain how catabolic glucocorticoid hormones and high intracellular AMP levels cooperate in inducing FOXO3 transcription and in activating the corresponding protein.

Indexed as

Gene Expression RegulationAdenosine MonophosphateAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsBase SequenceCell LineEnzyme ActivationForkhead Box Protein O3Forkhead Transcription FactorsGlucocorticoidsHumansImmediate-Early ProteinsInsulinIntracellular SpaceMaleAdenosine MonophosphateAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesForkhead Box Protein O3Forkhead Transcription FactorsFOXO3 protein, humanGlucocorticoidsImmediate-Early ProteinsInsulinProtein Serine-Threonine KinasesReceptors, GlucocorticoidSerum-Glucocorticoid Regulated KinasesSTK11 protein, human

Identifiers

PMID22848740
PMCPMC3407083
OpenAlexW2042985193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.